Tiagabine

Epilepsia

Volumn 40, Issue SUPPL. 5, 1999, Pages s17-s22

  Schachter, Steven C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Aminobutyric acid; Monotherapy; Partial seizures; Tiagabine;

Indexed keywords

ANTICONVULSIVE AGENT; TIAGABINE;

ASTHENIA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; HEADACHE; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO;

EID: 0032861993     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1999.tb00915.x     Document Type: Review

References (49)

1. Krogsgaard-Larsen P, Falch E, Larsson OM, Schousboe A. GABA uptake inhibitors: relevance to antiepileptic drug research. Epilepsy Res 1987;1:77-93.
2. Braestrup C, Nielsen EB, Sonnewald U, et al. (R)-N-(4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl)nipecotic acid binds with high affinity to the brain GABA uptake carrier. J Neurochem 1990;54: 639-47.
3. Giardina WJ. Anticonvulsant action of tiagabine, a new GABA-uptake inhibitor. J Epilepsy 1994;7:161-6.
4. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36:612-26.
5. Borden LA, Dhar TGM, Smith KE, Weinshank RL, Branchek TA, Gluchowski C. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994;269:219-24.
6. Brodie MJ. Tiagabine pharmacology in profile. Epilepsia 1995;36 (suppl 6):S7-9.
7. Morimoto K, Sato H, Yamamoto Y, Watanabe T, Suwaki H. Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 1997;38:966-74.
8. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJS, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991;196:257-66.
9. Faingold CL, Randall ME, Anderson CA. Blockade of GABA uptake with tiagabine inhibits audiogenic seizures and reduces neuronal firing in the inferior colliculus of the genetically epilepsyprone rat. Exp Neurol 1994;126:225-32.
10. Suzdak PD. Lack of tolerance to the anticonvulsant effects of tiagabine following chronic (21 day) treatment. Epilepsy Res 1994; 19:205-13.
11. Pierce MW, Suzdak PD, Gustavson LE, et al. Tiagabine. In: Pisani F, Perucca E, Avansini G, Richens A, eds. New antiepileptic drugs. Amsterdam: Elsevier, 1991:157-60.
12. Mengel H. Tiagabine. Epilepsia 1994;35(suppl 5):S81-4.
13. 14C] tiagabine by human hepatic microsomes [Abstract]. Epilepsia 1995;36(suppl 2):S159.
14. Samara EE, Gustavson LE, El-Shourbagy T, Locke C, Granneman GR, Sommerville KW. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy. Epilepsia 1998;39:868-73.
15. Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997;38:445-51.
16. Østergaard LH, Gram L, Dam M. Potential antiepileptic drugs. Tiagabine. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press, 1995:1057-61.
17. 14C tiagabine] after oral administration to human subjects [Abstract]. Epilepsia 1995;36(suppl 2):S158.
18. Cato A, Gustavson LE, Quian J, El-Shourbagy T, Kelly EA. Effect of renal impairment on the pharmacokinetics and tolerability of tiagabine. Epilepsia 1998;39:43-7.
19. Snel S, Jansen JA, Mengel HB, Richens A, Larsen S. The pharmacokinetics of tiagabine in healthy elderly volunteers and elderly patients with epilepsy. J Clin Pharmacol 1997;37:1015-20.
20. Gustavson LE, Boellner SW, Granneman GR, et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997;48:1032-7.
21. Schachter SC. Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia 1995;36(suppl 6):S2-6.
22. Gustavson LE, Mengel HB. Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses. Epilepsia 1995;36:605-11.
23. Gustavson LE, Cato A, Guenther HJ, et al. Lack of clinically important drug interactions between tiagabine and carbamazepine, phenytoin, or valproate [Abstract]. Epilepsia 1995;36(suppl 3): S159.
24. Snel S, Jansen JA, Pedersen PC, Jonkman JH, van Heiningen PN. Tiagabine, a novel antiepileptic agent: lack of pharmacokinetic interaction with digoxin. Eur J Clin Pharmacol 1998;54:355-7.
25. Mengel HB, Houston A, Back DJ. An evaluation of the interaction between tiagabine and oral contraceptives in female volunteers. J Pharm Med 1994;4:141-50.
26. Mengel H, Jansen JA, Sommerville K, et al. Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol [Abstract]. Epilepsia 1995;36(suppl 3):S160.
27. Richens A, Chadwick DW, Duncan JS, et al. Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res 1995;21:37-42.
28. Lassen LC, Sommerville K, Mengel HB, Edwards D, Nielsen B, Shu V. Summary of five controlled trials with tiagabine as adjunctive treatment of patients with partial seizures [Abstract]. Epilepsia 1995;36(suppl 3):S148.
29. Uthman BM, Rowan AJ, Ahmann PA, et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 1998;55:56-62.
30. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures. Arch Neurol 1997;54:595-601.
31. Kalviainen R, Brodie MJ, Duncan J, Chadwick D, Edwards D, Lyby K. A double-blind, placebo-controlled trial of tiagabine given three times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group. Epilepsy Res 1998;30: 31-40.
32. Ben-Menachem E. International experience with tiagabine add-on therapy. Epilepsia 1995;36(suppl 6):S14-21.
33. Schachter SC. Therapeutic choices and decisions. Presented at 22nd Int Epilepsy Cong Satell Symp, June 30, Dublin, 1997.
34. Somerville E. Lack of aggravation of epilepsy by tiagabine. Epilepsia 1998;39(suppl 6):S142.
35. Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:1025-31.
36. Biton V. Adjunctive tiagabine compared to phenytoin and carbamazepine in the multicenter, double-blind trial of complex partial seizures. Epilepsia 1998;39(suppl 6):S125-6.
37. Schachter SC, Deaton R, Sommerville K. Long-term use of tiagabine for partial seizures. Epilepsia 1997;38(suppl 8):S105-6.
38. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995;36 (suppl 6):S10-3.
39. Sommerville KW, Hearell M, Deaton R, Leppik IE. Adverse events with long-term tiagabine therapy [Abstract]. Epilepsia 1997;38(suppl 8):S106.
40. Collins SD. Absence of visual field defects in patients taking tiagabine. Epilepsia 1998;39(suppl 6):S146-7.
41. Eckardt KM, Steinhoff BJ. Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia 1998;39:671-4.
42. Schachter SC, Cahill WT, Wannamaker BB, Shu VS, Sommerville KW. Open-label dosage and tolerability study of tiagabine monotherapy in patients with refractory complex partial seizures. J Epilepsy 1998;11:248-55.
43. Brodie MJ. A monotherapy approach with tiagabine. Presented at 22nd Int Epilepsy Cong Satell Symp, June 30, Dublin, 1997.
44. Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998;39:33-42.
45. Collins SD, Donnelly J, Krupa D, Sommerville KW. Pregnancy and tiagabine exposure [Abstract]. Neurology 1997;48(suppl 2): A38.
46. Uldall P, Bulteau C, Pedersen SA, Dulac O, Meinild H, Lassen LC. Single-blind study of safety, tolerability, and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy. Epilepsia 1995;36(suppl 3):S147-8.
47. Boellner S, McCarty J, Mercante D, Sommerville K. Pilot study of tiagabine in children with partial seizures [Abstract]. Epilepsia 1996;37(suppl 4):S92.
48. Boellner SW, Deaton R, Sommerville KW. Long-term treatment of partial seizures with tiagabine in children [Abstract]. Epilepsia 1997;38(suppl 8):S208.
49. Schachter SC. Tiagabine: current status and potential clinical applications. Exp Opin Invest Drugs 1996;5:1377-87.